- Home
- PENG vs EVO Comparison
PENG vs EVO Comparison
Compare PENG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | EVO |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | Germany |
| Employees | 2900 | 4553 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 934.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PENG | EVO |
|---|---|---|
| Price | $52.93 | $3.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $27.78 | $7.00 |
| AVG Volume (30 Days) | ★ 3.0M | 85.0K |
| Earning Date | 04-01-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.55 | $1.37 |
| Revenue Next Year | $16.14 | $10.05 |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.04 | $2.31 |
| 52 Week High | $53.27 | $4.48 |
Technical Indicators
Market Signals| Indicator | PENG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 81.38 | 53.04 |
| Support Level | $19.31 | $2.88 |
| Resistance Level | $53.27 | $3.36 |
| Average True Range (ATR) | 4.23 | 0.09 |
| MACD | 0.42 | -0.01 |
| Stochastic Oscillator | 92.15 | 54.34 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.